Skip to main content

Perioperative Systemic Therapies for Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Network Meta-analysis

In brief

Enfortumab combo linked to 47% lower event hazard versus chemotherapy

In an analysis of eight randomized trials, enfortumab vedotin plus pembrolizumab was associated with a 47% lower hazard of events and a 35% lower hazard of death than gemcitabine-cisplatin; durvalumab plus chemotherapy also improved both outcomes. These indirect comparisons do not establish which regimen is best, and higher severe side effects with enfortumab were estimated from one direct trial.

Journal
Targeted oncology (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Akihiro Matsukawa, Keiichiro Mori, Takafumi Yanagisawa, Keiichiro Miyajima, Yuki Enei, Wataru Fukuokaya, et al.
PMID
43052561
DOI
10.1007/s11523-026-01270-9

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 22 November 2026): Perioperative systemic therapy evidence for muscle-invasive bladder cancer
  • Picked for Oncology and Radiation Oncology (paper of the day, 20 November 2026): Network meta-analysis of perioperative bladder cancer therapies

Abstract

BACKGROUND: Contemporary perioperative systemic therapies have improved outcomes in muscle-invasive bladder cancer (MIBC), but comparative evidence between novel strategies is limited. OBJECTIVE: To explore the comparative efficacy and safety of systemic treatment strategies initiated before radical cystectomy. PATIENTS AND METHODS: MEDLINE, Embase, Web of Science, and ClinicalTrials.gov were searched on 7 March 2026 for phase III randomized trials. Frequentist random-effects network meta-analysis evaluated overall survival (OS), event-free survival (EFS), and adverse events (AEs). Potential effect modifiers were compared across trials, and sensitivity analyses restricted the network to contemporary gemcitabine/cisplatin (GC)-controlled trials. Evidence certainty was assessed using Confidence in Network Meta-Analysis (CINeMA). PROSPERO: CRD420261277299. RESULTS: Eight RCTs were included. Compared with GC, enfortumab vedotin + pembrolizumab (EVP) and durvalumab + GC were associated with improved OS (hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.48-0.89; and HR 0.75; 95% CI 0.60-0.94, respectively) and EFS (HR 0.53; 95% CI 0.41-0.69; and HR 0.68; 95% CI 0.56-0.82, respectively). GC-referenced survival estimates were unchanged in sensitivity analyses. EVP had the highest survival P-scores, but rankings did not establish clinical superiority. The grade ≥ 3 AE estimate for EVP versus GC was (odds ratio; OR) 1.52 (95% CI 1.12-2.07), based on one direct trial. Population, treatment-exposure and outcome-ascertainment differences limited indirect comparisons. CONCLUSIONS: This exploratory analysis contextualizes randomized evidence for perioperative EVP and durvalumab + GC. Clinical heterogeneity limits conclusions about comparative superiority or tolerability. Rankings should be interpreted alongside effect estimates and trial-specific evidence.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.